Serum levels of ADAM12-S: Possible association with the initiation and progression of dermal fibrosis and interstitial lung disease in patients with systemic sclerosis

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 6, 2013, Pages 747-753

  Taniguchi, T ^a   Asano, Y ^a   Akamata, K ^a   Aozasa, N ^a   Noda, S ^a   Takahashi, T ^a   Ichimura, Y ^a   Toyama, T ^a   Sumida, H ^a   Kuwano, Y ^a   Yanaba, K ^a   Tada, Y ^a   Sugaya, M ^a   Kadono, T ^a   Sato, S ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

A DISINTERGRIN AND METALLOPROTEASE 12 S; ADAM PROTEIN; C REACTIVE PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SKIN FIBROSIS; SKINFOLD THICKNESS; SYSTEMIC SCLEROSIS;

ADAM PROTEINS; DISEASE PROGRESSION; FEMALE; FIBROSIS; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MEMBRANE PROTEINS; MIDDLE AGED; SCLERODERMA, SYSTEMIC; SKIN; TIME FACTORS;

EID: 84877619759     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2012.04558.x     Document Type: Article

References (27)

1. Asano Y,. Future treatments in systemic sclerosis. J Dermatol 2010; 37: 54-70.
2. Takehara K,. Hypothesis: pathogenesis of systemic sclerosis. J Rheumatol 2003; 30: 755-759.
3. Yagami-Hiromasa T, Sato T, Kurisaki T, et al. A metalloprotease- disintegrin participating in myoblast fusion. Nature 1995; 377: 652-656.
4. Gilpin BJ, Loechel F, Mattei MG, et al. A novel, secreted form of human ADAM 12 (meltrin alpha) provokes myogenesis in vivo. J Biol Chem 1998; 273: 157-166.
5. Kveiborg M, Albrechtsen R, Couchman JR, et al. Cellular roles of ADAM12 in health and disease. Int J Biochem Cell Biol 2008; 40: 1685-1702.
6. Laigaard J, Sørensen T, Fröhlich C, et al. ADAM12: a novel first-trimester maternal serum marker for Down syndrome. Prenat Diagn 2003; 23: 1086-1091.
7. Arribas J, Bech-Serra JJ, Santiago-Josefat B,. ADAMs, cell migration and cancer. Cancer Metastasis Rev 2006; 25: 57-68.
8. Fedak PW, Moravec CS, McCarthy PM, et al. Altered expression of disintegrin metalloproteinases and their inhibitor in human dilated cardiomyopathy. Circulation 2006; 113: 238-245.
9. Roy R, Wewer UM, Zurakowski D, et al. ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J Biol Chem 2004; 279: 51323-51330.
10. Shi Z, Xu W, Loechel F, et al. ADAM 12, a disintegrin metalloprotease, interacts with insulin-like growth factor-binding protein-3. J Biol Chem 2000; 275: 18574-18580.
11. Loechel F, Fox JW, Murphy G, et al. ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. Biochem Biophys Res Commun 2000; 278: 511-515.
12. Jones JI, Clemmons DR,. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16: 3-34.
13. Harsha A, Stojadinovic O, Brem H, et al. ADAM12: a potential target for the treatment of chronic wounds. J Mol Med (Berl) 2008; 86: 961-969.
14. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-205.
15. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23: 581-590.
16. Steen VD, Powell DL, Medsger TA,. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988; 31: 196-203.
17. Sato S, Ihn H, Kikuchi K, Takehara K,. Antihistone antibodies in systemic sclerosis. Association with pulmonary fibrosis. Arthritis Rheum 1994; 37: 391-394.
18. Clements PJ, Lachenbruch PA, Seibold JR, et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993; 20: 1892-1896.
19. Kazerooni EA, Martinez FJ, Flint A, et al. Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 1997; 169: 977-983.
20. Steen VD, Medsger TA,. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43: 2437-2444.
21. Hamaguchi Y, Fujimoto M, Matsushita T, et al. Elevated serum insulin-like growth factor (IGF-1) and IGF binding protein-3 levels in patients with systemic sclerosis: possible role in development of fibrosis. J Rheumatol 2008; 35: 2363-2371.
22. Zhu KQ, Engrav LH, Tamura RN, et al. Further similarities between cutaneous scarring in the female, red Duroc pig and human hypertrophic scarring. Burns 2004; 30: 518-530.
23. Fakhoury H, Hillarby MC, Weiss JB,. Increased gelatinase activity in systemic sclerosis dermal fibroblast cultures with unaltered gelatinase A mRNA expression. J Dermatol Sci 2002; 29: 62-69.
24. Wilhelm SM, Collier IE, Marmer BL, et al. SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J Biol Chem 1989; 264: 17213-17221.
25. Prescott RJ, Freemont AJ, Jones CJ, et al. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 1992; 166: 255-263.
26. Le Pabic H, Bonnier D, Wewer UM, et al. ADAM12 in human liver cancers: TGF-beta-regulated expression in stellate cells is associated with matrix remodeling. Hepatology 2003; 37: 1056-1066.
27. Solomon E, Li H, Muggy SD, et al. The role of SnoN in transforming growth factor beta1-induced expression of metalloprotease-disintegrin ADAM12. J Biol Chem 2010; 285: 21969-21977.